Staffing & Employment Services
Compare Stocks
4 / 10Stock Comparison
IPDN vs CCRN vs AMN vs RCMT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Conglomerates
IPDN vs CCRN vs AMN vs RCMT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Staffing & Employment Services | Medical - Care Facilities | Medical - Care Facilities | Conglomerates |
| Market Cap | $964K | $326M | $811M | $213M |
| Revenue (TTM) | $6M | $1.05B | $2.73B | $319M |
| Net Income (TTM) | $-2.36B | $-95M | $-96M | $16M |
| Gross Margin | 44.1% | 18.7% | 25.7% | 27.2% |
| Operating Margin | -136.0% | -0.3% | -3.5% | 7.9% |
| Forward P/E | — | 103.4x | 10.3x | 13.0x |
| Total Debt | $279K | $2M | $803M | $26M |
| Cash & Equiv. | $2M | $109M | $34M | $3M |
IPDN vs CCRN vs AMN vs RCMT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Professional Divers… (IPDN) | 100 | 4.2 | -95.8% |
| Cross Country Healt… (CCRN) | 100 | 166.6 | +66.6% |
| AMN Healthcare Serv… (AMN) | 100 | 47.3 | -52.7% |
| RCM Technologies, I… (RCMT) | 100 | 2239.6 | +2139.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IPDN vs CCRN vs AMN vs RCMT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IPDN lags the leaders in this set but could rank higher in a more targeted comparison.
CCRN is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 1 yrs, beta 0.78
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
- Beta 0.78, current ratio 3.78x
- Beta 0.78 vs IPDN's 1.35, lower leverage
AMN is the clearest fit if your priority is value.
- Lower P/E (10.3x vs 13.0x)
RCMT carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 14.7%, EPS growth 28.0%, 3Y rev CAGR 3.9%
- 494.1% 10Y total return vs CCRN's -28.1%
- 14.7% revenue growth vs CCRN's -21.6%
- 5.1% margin vs IPDN's -135.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 14.7% revenue growth vs CCRN's -21.6% | |
| Value | Lower P/E (10.3x vs 13.0x) | |
| Quality / Margins | 5.1% margin vs IPDN's -135.9% | |
| Stability / Safety | Beta 0.78 vs IPDN's 1.35, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +74.3% vs IPDN's -58.2% | |
| Efficiency (ROA) | 12.5% ROA vs IPDN's -194.3%, ROIC 26.9% vs -68.4% |
IPDN vs CCRN vs AMN vs RCMT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
IPDN vs CCRN vs AMN vs RCMT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
RCMT leads in 3 of 6 categories
AMN leads 1 • IPDN leads 0 • CCRN leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
RCMT leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMN is the larger business by revenue, generating $2.7B annually — 429.7x IPDN's $6M. RCMT is the more profitable business, keeping 5.1% of every revenue dollar as net income compared to IPDN's -135.9%. On growth, IPDN holds the edge at +1021.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $6M | $1.1B | $2.7B | $319M |
| EBITDAEarnings before interest/tax | -$2.3B | $13M | $62M | $27M |
| Net IncomeAfter-tax profit | -$2.4B | -$95M | -$96M | $16M |
| Free Cash FlowCash after capex | -$5M | $42M | $234M | $17M |
| Gross MarginGross profit ÷ Revenue | +44.1% | +18.7% | +25.7% | +27.2% |
| Operating MarginEBIT ÷ Revenue | -136.0% | -0.3% | -3.5% | +7.9% |
| Net MarginNet income ÷ Revenue | -135.9% | -9.0% | -3.5% | +5.1% |
| FCF MarginFCF ÷ Revenue | -0.3% | +4.0% | +8.6% | +5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1021.2% | -23.6% | +1.8% | +12.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -26026.4% | -20.3% | +95.9% | +116.2% |
Valuation Metrics
AMN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, AMN's 8.3x EV/EBITDA is more attractive than CCRN's 16.5x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $964,271 | $326M | $811M | $213M |
| Enterprise ValueMkt cap + debt − cash | -$487,572 | $220M | $1.6B | $236M |
| Trailing P/EPrice ÷ TTM EPS | -0.38x | -3.45x | -8.46x | 13.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 103.37x | 10.31x | 12.96x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.32x |
| EV / EBITDAEnterprise value multiple | — | 16.49x | 8.33x | 8.36x |
| Price / SalesMarket cap ÷ Revenue | 0.14x | 0.31x | 0.30x | 0.67x |
| Price / BookPrice ÷ Book value/share | 0.20x | 1.01x | 1.26x | 4.97x |
| Price / FCFMarket cap ÷ FCF | — | 6.76x | 3.47x | 12.25x |
Profitability & Efficiency
RCMT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
RCMT delivers a 40.9% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-284 for IPDN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMN's 1.25x. On the Piotroski fundamental quality scale (0–9), RCMT scores 8/9 vs AMN's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -284.3% | -24.3% | -14.7% | +40.9% |
| ROA (TTM)Return on assets | -194.3% | -17.9% | -4.3% | +12.5% |
| ROICReturn on invested capital | -68.4% | -0.9% | +1.6% | +26.9% |
| ROCEReturn on capital employed | -65.9% | -0.8% | +2.0% | +31.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 5 | 8 |
| Debt / EquityFinancial leverage | 0.06x | 0.01x | 1.25x | 0.56x |
| Net DebtTotal debt minus cash | -$1M | -$106M | $769M | $23M |
| Cash & Equiv.Liquid assets | $2M | $109M | $34M | $3M |
| Total DebtShort + long-term debt | $279,312 | $2M | $803M | $26M |
| Interest CoverageEBIT ÷ Interest expense | -66476.01x | -1.56x | -1.22x | 9.05x |
Total Returns (Dividends Reinvested)
RCMT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RCMT five years ago would be worth $88,265 today (with dividends reinvested), compared to $242 for IPDN. Over the past 12 months, RCMT leads with a +74.3% total return vs IPDN's -58.2%. The 3-year compound annual growth rate (CAGR) favors RCMT at 35.0% vs IPDN's -74.7% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -42.1% | +25.4% | +38.7% | +51.1% |
| 1-Year ReturnPast 12 months | -58.2% | -26.6% | +7.1% | +74.3% |
| 3-Year ReturnCumulative with dividends | -98.4% | -57.0% | -76.8% | +145.8% |
| 5-Year ReturnCumulative with dividends | -97.6% | -37.2% | -76.3% | +782.6% |
| 10-Year ReturnCumulative with dividends | -99.0% | -28.1% | -44.1% | +494.1% |
| CAGR (3Y)Annualised 3-year return | -74.7% | -24.5% | -38.5% | +35.0% |
Risk & Volatility
Evenly matched — CCRN and RCMT each lead in 1 of 2 comparable metrics.
Risk & Volatility
CCRN is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than IPDN's 1.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCMT currently trades 92.3% from its 52-week high vs IPDN's 6.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.35x | 0.78x | 1.08x | 1.30x |
| 52-Week HighHighest price in past year | $12.39 | $14.99 | $23.74 | $32.50 |
| 52-Week LowLowest price in past year | $0.68 | $7.43 | $14.87 | $17.05 |
| % of 52W HighCurrent price vs 52-week peak | +6.2% | +67.4% | +88.4% | +92.3% |
| RSI (14)Momentum oscillator 0–100 | 35.0 | 67.4 | 60.3 | 72.6 |
| Avg Volume (50D)Average daily shares traded | 82K | 451K | 839K | 66K |
Analyst Outlook
Evenly matched — CCRN and RCMT each lead in 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CCRN as "Hold", AMN as "Buy", RCMT as "Buy". Consensus price targets imply 7.3% upside for AMN (target: $23) vs 4.9% for CCRN (target: $11).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | — | $10.61 | $22.50 | — |
| # AnalystsCovering analysts | — | 14 | 17 | 3 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.3% | +3.5% |
RCMT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AMN leads in 1 (Valuation Metrics). 2 tied.
IPDN vs CCRN vs AMN vs RCMT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IPDN or CCRN or AMN or RCMT a better buy right now?
For growth investors, RCM Technologies, Inc.
(RCMT) is the stronger pick with 14. 7% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). RCM Technologies, Inc. (RCMT) offers the better valuation at 14. 0x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate AMN Healthcare Services, Inc. (AMN) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IPDN or CCRN or AMN or RCMT?
On forward P/E, AMN Healthcare Services, Inc.
is actually cheaper at 10. 3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — IPDN or CCRN or AMN or RCMT?
Over the past 5 years, RCM Technologies, Inc.
(RCMT) delivered a total return of +782. 6%, compared to -97. 6% for Professional Diversity Network, Inc. (IPDN). Over 10 years, the gap is even starker: RCMT returned +494. 1% versus IPDN's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IPDN or CCRN or AMN or RCMT?
By beta (market sensitivity over 5 years), Cross Country Healthcare, Inc.
(CCRN) is the lower-risk stock at 0. 78β versus Professional Diversity Network, Inc. 's 1. 35β — meaning IPDN is approximately 74% more volatile than CCRN relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 125% for AMN Healthcare Services, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — IPDN or CCRN or AMN or RCMT?
By revenue growth (latest reported year), RCM Technologies, Inc.
(RCMT) is pulling ahead at 14. 7% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: AMN Healthcare Services, Inc. grew EPS 35. 6% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, RCMT leads at 3. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IPDN or CCRN or AMN or RCMT?
RCM Technologies, Inc.
(RCMT) is the more profitable company, earning 5. 1% net margin versus -37. 3% for Professional Diversity Network, Inc. — meaning it keeps 5. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCMT leads at 7. 9% versus -38. 6% for IPDN. At the gross margin level — before operating expenses — IPDN leads at 60. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IPDN or CCRN or AMN or RCMT more undervalued right now?
On forward earnings alone, AMN Healthcare Services, Inc.
(AMN) trades at 10. 3x forward P/E versus 103. 4x for Cross Country Healthcare, Inc. — 93. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMN: 7. 3% to $22. 50.
08Which pays a better dividend — IPDN or CCRN or AMN or RCMT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is IPDN or CCRN or AMN or RCMT better for a retirement portfolio?
For long-horizon retirement investors, Cross Country Healthcare, Inc.
(CCRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78)). Both have compounded well over 10 years (CCRN: -28. 1%, IPDN: -99. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IPDN and CCRN and AMN and RCMT?
These companies operate in different sectors (IPDN (Industrials) and CCRN (Healthcare) and AMN (Healthcare) and RCMT (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: IPDN is a small-cap quality compounder stock; CCRN is a small-cap quality compounder stock; AMN is a small-cap quality compounder stock; RCMT is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.